Clinical trials are a critical component in expanding treatment options for people with all types of cancer. Because all new therapies must be evaluated by clinical trials, the greater the number of people who participate, the faster emerging anticancer therapies can be brought to market.
As a part of the US Oncology Research Network, we are at the forefront of cancer research and offer participation in trials for many different types of cancer. We believe it is important to provide access to promising new therapies and expand treatment options for people in our community.
Trials are offered in all disease types including Breast, Lung, Lymphoma, Melanoma, Myeloma, Prostate, Sarcomas, Solid Tumors and Urothelial.
BREAST CANCER
Faslodex +/- Dasatinib PostMen HR+ MBC
Phase II Randomized Trial of Fulvestrant With Or Without Dasatinib in Men and Post-menopausal women Who Have Hormove Receptor-Positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor.
Adj. TAC vs TC vs TC+BeV
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative HER2-Negative Breast Cancer.
Peg-SN38 Pretreated Metastatic Breast Cancer Patients
A Phase II, Open-Label Study of EZN-2208 (PEG-SN38) in Patients with Previously Treated Metastatic Breast Cancer.
BETH Chemo/Trast +/- Bev in Adjuvant HER2+ Breast Cancer Patients
A Multi-center Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive of High Risk Node-negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
A Randomized Double Blind Placebo-Controlled Trial of Neratinib (HKI-272) Following Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.
Tras/Pac +/- RAD001 HER2+ MBC - BOLERO 1
CRAD001-J2301: A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial Of Everolimus In Combination With Trastuzumab and Paclitaxel, As First Line Therapy In Women With HER2-Positive Locally Advanced or Metastatic Breast Cancer.
Lapat+Trast vs Trast Suppression in HER2+ Breast Cancer Patients
A Randomized, Phase III, Open-label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-Line Trastuzumabe plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer.
TAILORx - Assigning Individualized Options for Trt, Node -, ER+, PR+
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial.
BRE 154 - Ph II Pac/Bev +/- RAD001
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients with HER2-Negative Metastatic Breast Cancer.
STRIDE - Hormonal Treatment +/- STIMUVAX
A Randomized, Double-Blind, Controlled Phase III Study of Stimuvax (L=BLP25 or BLP25 Liposome Vaccine) In Combination With Hormonal Treatment Versus Hormonal Treatement Alone for First-Line Therapy of Post-Menopausal Women With Estrogen Receptor (ER)- Positive and/or Progresterone Receptor (PGR)-Positive, Inoperable Locally Advanced, Recurrent, Or Metastatic Breast Cancer.
A Pilot Study Utilizing Molecular Profiling by IHC, FISH, DNA Microarray and Reverse Phase Protein Microarray (RPMA) of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer.
LUNG CANCER
Aranesp in Non-Small Cell Lung Cancer
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safet and Efficacy of Darbepoetin Alfa Administered at 500 mg Once-Every-Three-Weeks in Anemic Subjects With Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.
Pam/Carbo/Bev vs Tax/Carbo/Bev as First-Line in Non-Small Cell Lung Cancer
Randomized, Open-label, Phase III Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintanance Bevacizumab in Patients with Stage IIIB or IV Non-squamous Non-Small Cell Lung Cancer (H3E-MC-JMHD)
Docetaxel +/- ASA404 as Second-Line in Non-Small Cell Lung Cancer
A Phase III, Randomized, Double-Blind, Placebo Controlled Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Locally Advanced or Metastatic (Stage IIIB/IV) Non-Small Cell Lung Cancer.
Eribulin wth Intermittent Erlotinib in Non-Small Cell Lung Cancer
A Phase II, Multicenter, Randomized Study of Two Different Dose Regimens of Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer.
START - Study of vaccine STIMUVAX in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
A Multi-center Phase III Randomized, Double-Blind Placebo-Controlled Study of The Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) In Non-Small Cell Lung Cancer Patients with Unresectable Stage III Disease.
MELANOMA
Tasisulam vs Paclitaxel as 2nd Line in Melanoma
A Randomized, Phase III Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma.
MYELOMA
Multiple Myeloma (MM) Connect Registry
The Multiple Myeloma Disase Registry - Regsitry Protocol.
Bendamustine + Bortezomib Relapsed/Refractory Multiple Myeloma
An open-label study of Bendamustine combined with Bortezomib for patients with relapsed/refractory Multiple Myeloma.
Tissue Analysis for Multiple Myeloma
Myeloma Drug Target Signal Pathway Analysis.
NON-HODGKIN'S LYMPHOMA
An open-label study to evaluate the efficacy and safety of treatment with Bendamustine in combination wtih Ofatumumab in previously untreated patients with indolent B-Cell Non-Hodgkin's Lymphoma.
PROSTATE CANCER
Docetaxel/Pred +/- Lenalidomide as First-Line in Castrate-Resistant Prostate Cancer
A phase III study to evaluate the efficacy and safety of Docetaxel and Prednisone with or without Lenalidomide in patients with Castrate-Resistant Prostate Cancer (CRPC).
SARCOMAS
A pivotal trial to determine the efficacy and safety of AP23573 when administered as maintenance therapy to patients with Metastatic Soft Tissue or Bone Sarcomas.
SOLID TUMORS
Rd Disc XL184 Advanced Solid Tumors
A randomized, discontinuation study of XL184 in patients with Advanced Solid Tumors.
UROTHELIAL CANCER
BI 6727 in Second-Line Urothelial Cancer
An open-lable, single-arm, phase II trial of intravenous BI 6727 in patients with locally advanced, metastatic or recurrent Urothelial Cancer of the bladder, renal pelvis or ureters after failure or prior chemotherapy.
